-
Infection and Drug Resistance
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Role of posaconazole in the treatment of oropharyngeal candidiasis
Review
(1832) Views (502) Full article downloads
Authors: Voichita Ianas, Kathryn R Matthias, Stephen A Klotz
Published Date June 2010
Volume 2010:3 Pages 45 - 51
DOI: http://dx.doi.org/10.2147/IDR.S10588
Voichita Ianas1, Kathryn R Matthias2, Stephen A Klotz1
1Section of Infectious Diseases and Department of Medicine, 2School of Pharmacy, University of Arizona, Tucson, Arizona, USA
Abstract: Posaconazole is the newest azole antifungal approved by the US Food and Drug Administration, and possesses a broad spectrum of activity against numerous yeasts and filamentous fungi. It is available as an oral suspension and is generally well tolerated by patients, but gastrointestinal absorption is sometimes inadequate and remains a clinical concern in treating deep-seated infections. It is used routinely and effectively for the prophylaxis of invasive fungal infections in immunosuppressed hosts and is an effective treatment of oropharyngeal candidiasis, including azole-resistant disease.
Keywords: posaconazole, azole, yeasts, filamentous fungi
Readers of this article also read:
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection
Prevention strategies for antimicrobial resistance: a systematic review of the literature
Drug resistance in community-acquired respiratory tract infections: role for an emerging antibacterial
Occult hepatitis B virus infection in Egyptian hemodialysis patients with or without hepatitis C virus infection
Boceprevir in the treatment of chronic hepatitis C virus infection
Management of oropharyngeal candidiasis with localized oral miconazole therapy: efficacy, safety, and patient acceptability
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
High prevalence of extended-spectrum β-lactamase-producing pathogens: results of a surveillance study in two hospitals in Ujjain, India
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi
- Treatment of drug-resistant tuberculosis
- Subset-directed antiviral treatment of 142 herpesvirus patients with chronic fatigue syndrome
- High prevalence of multidrug-resistant MRSA in a tertiary care hospital of northern India




